Skip to main content

Table 2 Estimated proportion of patients with relapse of upper gastrointestinal symptoms

From: Maintenance treatment with esomeprazole following initial relief of non-steroidal anti-inflammatory drug-associated upper gastrointestinal symptoms: the NASA2 and SPACE2 studies

 

NASA2 study

p value versus placebo

SPACE2 study

p value versus placebo

Placebo

38.2%

-

39.8%

-

Esomeprazole 20 mg

28.3%

0.04

30.7%

0.07

Esomeprazole 40 mg

24.3%

0.004

28.4%

0.05

  1. Kaplan-Meier life-table estimates of proportion of patients with relapse of pain, discomfort, or burning in the upper abdomen throughout 6 months of treatment with esomeprazole 20 mg, esomeprazole 40 mg, or placebo and log-rank comparisons for the individual studies. NASA, Nexium Anti-inflammatory Symptom Amelioration; SPACE, Symptom Prevention by Acid Control with Esomeprazole.